Tag Archive for: Zepbound

The company unveiled detailed findings from the Phase III SURMOUNT-OSA program, showing that its blockbuster weight-loss drug Zepbound (tirzepatide) could significantly improve disease severity in patients with moderate-to-severe obstructive sleep apnea and obesity.

Eli Lilly on Thursday announced it has filed additional lawsuits against medical spas, wellness centers and other similar entities, which allegedly have been selling unapproved compounded versions of the pharma’s best-selling GLP-1 receptor agonist tirzepatide.

About one-third of U.S. employer health plans are offering coverage of GLP-1 drugs for both diabetes management and weight loss, up from last year, according to a survey of global employers released on Thursday by the International Foundation of Employee Benefit Plans.

M&A deal growth, the AI revolution, and the market surge of GLP-1 weight-loss medicines represent a trio of hot trends propelling the biopharmaceutical industry.

Evidence that weight-loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound can cut heart disease risk, treat sleep apnea and address other health issues may help convince more men to use them, five doctors who prescribe the medicines regularly told Reuters.

Tuesday’s NICE recommendation for Zepbound comes after the agency in late 2023 also backed the use of its sister tirzepatide brand Mounjaro for type 2 diabetes.

There are several other drug developers aiming to join the weight loss drug bandwagon. The following is a list of publicly listed companies targeting the next big blockbuster opportunity.

Anti-obesity drugs have revolutionized the market in the last few years, and have been identified as the emerging industry trend likely to have the greatest impact on the biopharmaceutical industry in the next 12 months, according to GlobalData.

Lilly said it expects the drugs to remain in tight supply, but plans for significant production increases in the second half of the year.

According to the agency’s website, most doses of Eli Lilly’s diabetes drug Mounjaro and weight-loss drug Zepbound would be in limited supply through the second quarter of this year due to increased demand.